Viking Therapeutics, Inc. Net Change in Cash
Viking Therapeutics, Inc. (VKTX) reported Net Change in Cash of $32.90 million for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-07-26.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2023-07-26
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$18.26M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2022-03-31 was -$13.92M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2021-03-31 was -$12.31M, a 278.88% decline year-over-year.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2020-03-31 was $6.88M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was $10.52M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2021 was -$2.75M, a 113.24% decline from fiscal 2020.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2020 was $20.74M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2019 was -$16.40M, a 203.87% decline from fiscal 2018.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-06-30 | $32.90M 10-Q · filed 2023-07-26 | |||
| 2023-03-31 | -$18.26M 10-Q · filed 2023-04-26 | |||
| 2022-12-31 | $10.52M 10-K · filed 2023-02-10 | |||
| 2022-09-30 | $3.44M 10-Q · filed 2022-10-26 | |||
| 2022-06-30 | -$9.97M 10-Q · filed 2023-07-26 | |||
| 2022-03-31 | -$13.92M 10-Q · filed 2023-04-26 | |||
| 2021-12-31 | -$2.75M 10-K · filed 2023-02-10 | |||
| 2021-09-30 | -$17.85M 10-Q · filed 2022-10-26 | |||
| 2021-06-30 | -$20.29M 10-Q · filed 2021-07-28 | |||
| 2021-03-31 | -$12.31M 10-Q · filed 2022-04-27 | |||
| 2020-12-31 | $20.74M 10-K · filed 2022-02-09 | |||
| 2020-09-30 | -$4.51M 10-Q · filed 2021-11-03 | |||
| 2020-06-30 | $10.41M 10-Q · filed 2021-07-28 | |||
| 2020-03-31 | $6.88M 10-Q · filed 2021-04-28 | |||
| 2019-12-31 | -$16.40M 10-K · filed 2021-02-17 | |||
| 2019-09-30 | $6.17M 10-Q · filed 2020-10-28 | |||
| 2019-06-30 | -$5.66M 10-Q · filed 2020-07-29 | |||
| 2019-03-31 | -$10.44M 10-Q · filed 2020-04-30 | |||
| 2018-12-31 | $15.79M 10-K · filed 2020-02-26 | |||
| 2018-09-30 | $160.52M 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |